...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Clinical and pathological response to primary chemotherapy in patients with locally advanced breast cancer grouped according to hormonal receptors, Her2 status, grading and Ki-67 proliferation index.
【24h】

Clinical and pathological response to primary chemotherapy in patients with locally advanced breast cancer grouped according to hormonal receptors, Her2 status, grading and Ki-67 proliferation index.

机译：根据荷尔蒙受体，Her2状态，分级和Ki-67增殖指数对局部晚期乳腺癌患者对原发化疗的临床和病理反应进行分组。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVES: Biological markers that reliably predict clinical and pathological response to primary systemic therapy may have considerable clinical potential; this study evaluated response compared to expression of ER, PgR and Her2, grading and Ki-67 proliferation index before and after neoadjuvant chemotherapy in patients with locally advanced breast cancer (LABC). PATIENTS AND METHODS: Fifty-five patients received neoadjuvant chemotherapy for LABC. The incidence of clinical and pathological responses was assessed with respect to basal clinical stage, absent/low vs. high ER and PgR status, low vs. high proliferation index, grading and Her2 overexpression. RESULTS: Overall, 30 patients (54%) underwent downstaging of their primary tumor; pathological complete remission was observed in only one patient with Her2 positive breast tumor. Patients with pre-treatment Ki-67 >20%, Her2 overexpression, T2b/T3 vs. T4 clinical stage achieved higher response rate. CONCLUSION: The future of neoadjuvant therapy lies in tailoring treatment to individual patients by identifying response predictors; although the number of patients reported is small, this study confirms that clinical stage at diagnosis, Ki-67 reduction and Her2 overexpression are predictive of tumor response to neoadjuvant regimens.
机译：目的：能够可靠地预测对主要全身治疗的临床和病理反应的生物学标记物可能具有相当大的临床潜力。这项研究评估了局部晚期乳腺癌（LABC）患者新辅助化疗前后与ER，PgR和Her2的表达，分级和Ki-67增殖指数相比的反应。患者与方法：55例接受LABC新辅助化疗的患者。根据基础临床阶段，ER / PgR状态不存在/低与高，增殖指数低与高，分级和Her2过表达来评估临床和病理反应的发生率。结果：总体上，有30例患者（54％）的原发肿瘤分期降低;仅一名Her2阳性乳腺肿瘤患者观察到病理完全缓解。治疗前Ki-67> 20％，Her2过表达，T2b / T3 vs. T4临床阶段的患者获得更高的缓解率。结论：新辅助疗法的未来在于通过确定反应预测因子为个体患者量身定制治疗方案。尽管报告的患者人数很少，但这项研究证实，诊断时的临床阶段，Ki-67降低和Her2过表达可预测肿瘤对新辅助方案的反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号